| Followers | 19 |
| Posts | 6566 |
| Boards Moderated | 1 |
| Alias Born | 05/23/2019 |
Monday, January 30, 2023 5:16:16 AM
WISE WQLF SAYS; Lets not forget the other two CW Labs collaborators that are now part of the Joel Stanley AJNA Bioscience organization that had been formed and funded by Charlottes Web and now it appears has broken ties with CW Holding Company and his going to benefit from the fruits of the Charlottes Web shareholders. IMO Have Mercy WQLF Ahooooooo
FYI: For further and Quicker Reference. Please go to Sticky Notes for more details YQU Understand. Have Mercy WQLF Ahooooooo
WISE WQLF’s Due Diligence on CW Labs and AJNA Bioscience
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171067686
Jeff Lombardo, PharmD, BCOP
VP Pharmacology
Research Assistant Professor in Translational Pharmacology, University at Buffalo; 20+ years in oncology clinical work
Dr. Joong J Fang Said; Staci Gruber and Orrin Devinsky
Our Scientific Advisory Board
https://www.ajnabiosciences.com/about-us
Staci Gruber, PhD
MCLEAN HOSPITAL - HARVARD
MEDICAL SCHOOL
Director of Cognitive and Clinical Neuroimaging Core; Director of Marijuana Investigations for Neuroscientific Discovery
Orrin Devinsky, MD
Chief Medical Advisor
Director Comprehensive Epilepsy Center at NYU Langone, Lead Investigator for Epidiolex, Professor at NYU Grossman School of Medicine
Gene Morse, PharmD, FCCP, BCPS
UNIVERSITY AT BUFFALO
SUNY Distinguished Professor; Director of Biomedical Sciences, Translational Pharmacology Research Core
Charlotte's Web's CW Labs Announce New Scientific Collaboration Researching Hemp CBD Efficacy
FEBRUARY 26, 2021
Harvard Medical School's Dr. Staci Gruber, Ph.D. is lead investigator
“ Two distinct clinical trials will be overseen by lead researcher/investigator Dr. Staci A. Gruber, Ph. D, Associate Professor of Psychiatry at Harvard Medical School and Director of the MIND program at McLean Hospital in Belmont, Mass. These two studies will investigate the efficacy of a custom-formulated, hemp-derived high-CBD product. Clinical trial results are to be published in 2022. Dr. Gruber is also conducting a number of other studies, including a longitudinal observational study of Veterans who use a Charlotte's Web product.
Dr. Gruber's Marijuana Investigations for Neuroscientific Discovery (MIND) Program, established in 2014, is the first of its kind, and is dedicated to studying the long-term impact of cannabis and cannabinoids for medical and adult use which utilizes various clinical and cognitive tools as well as multimodal neuroimaging techniques.
"We are honored to be working with Dr. Gruber, Harvard Medical School and McLean Hospital on these important clinical trials," said Tim Orr, President of Charlotte's Web's CW Labs divison.”
https://investors.charlottesweb.com/press-releases/press-release-details/2021/Charlottes-Webs-CW-Labs-Announce-New-Scientific-Collaboration-Researching-Hemp-CBD-Efficacy/default.aspx
FYI: For further and Quicker Reference. Please go to Sticky Notes for more details YQU Understand. Have Mercy WQLF Ahooooooo
WISE WQLF’s Due Diligence on CW Labs and AJNA Bioscience
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171067686
Jeff Lombardo, PharmD, BCOP
VP Pharmacology
Research Assistant Professor in Translational Pharmacology, University at Buffalo; 20+ years in oncology clinical work
Dr. Joong J Fang Said; Staci Gruber and Orrin Devinsky
Our Scientific Advisory Board
https://www.ajnabiosciences.com/about-us
Staci Gruber, PhD
MCLEAN HOSPITAL - HARVARD
MEDICAL SCHOOL
Director of Cognitive and Clinical Neuroimaging Core; Director of Marijuana Investigations for Neuroscientific Discovery
Orrin Devinsky, MD
Chief Medical Advisor
Director Comprehensive Epilepsy Center at NYU Langone, Lead Investigator for Epidiolex, Professor at NYU Grossman School of Medicine
Gene Morse, PharmD, FCCP, BCPS
UNIVERSITY AT BUFFALO
SUNY Distinguished Professor; Director of Biomedical Sciences, Translational Pharmacology Research Core
Charlotte's Web's CW Labs Announce New Scientific Collaboration Researching Hemp CBD Efficacy
FEBRUARY 26, 2021
Harvard Medical School's Dr. Staci Gruber, Ph.D. is lead investigator
“ Two distinct clinical trials will be overseen by lead researcher/investigator Dr. Staci A. Gruber, Ph. D, Associate Professor of Psychiatry at Harvard Medical School and Director of the MIND program at McLean Hospital in Belmont, Mass. These two studies will investigate the efficacy of a custom-formulated, hemp-derived high-CBD product. Clinical trial results are to be published in 2022. Dr. Gruber is also conducting a number of other studies, including a longitudinal observational study of Veterans who use a Charlotte's Web product.
Dr. Gruber's Marijuana Investigations for Neuroscientific Discovery (MIND) Program, established in 2014, is the first of its kind, and is dedicated to studying the long-term impact of cannabis and cannabinoids for medical and adult use which utilizes various clinical and cognitive tools as well as multimodal neuroimaging techniques.
"We are honored to be working with Dr. Gruber, Harvard Medical School and McLean Hospital on these important clinical trials," said Tim Orr, President of Charlotte's Web's CW Labs divison.”
https://investors.charlottesweb.com/press-releases/press-release-details/2021/Charlottes-Webs-CW-Labs-Announce-New-Scientific-Collaboration-Researching-Hemp-CBD-Efficacy/default.aspx
Bearish
Recent CWBHF News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/16/2026 07:03:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/16/2026 07:03:14 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/16/2026 07:02:48 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/14/2026 04:30:15 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/06/2026 09:07:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 06:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 06:31:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 06:29:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 11:18:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 09:30:13 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/01/2026 09:29:45 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 11:08:26 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 11:07:30 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 11:07:11 AM
- Charlotte's Web Reports 2025 Fourth Quarter and Full Year Financial Results • PR Newswire (US) • 03/31/2026 11:07:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 10:46:21 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 10:45:01 AM
- Charlotte's Web Announces Transaction with BAT: Debenture Conversion and US$10M Equity Investment to Strengthen Balance Sheet • PR Newswire (US) • 03/31/2026 02:59:00 AM
- Charlotte's Web 2025 Fourth Quarter and Year-End Earnings Call and Webcast Notice • PR Newswire (US) • 03/24/2026 01:15:00 PM
- Charlotte's Web Welcomes New CMS Guidance, Advancing Access to Eligible Full‑Spectrum Hemp Products • PR Newswire (US) • 03/21/2026 01:53:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2026 03:19:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 12:14:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:07:22 PM
